Troy Edward Wilson net worth and biography

Troy Wilson Biography and Net Worth

Director of Puma Biotechnology

Dr. Wilson was appointed as a director and as a member of the Audit Committee of Puma Biotechnology on October 18, 2013. Dr. Wilson has been the President and Chief Executive Officer and a member of the board of directors of Kura Oncology, Inc., a public reporting clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers, since August 2014. He has also been the President and Chief Executive Officer and a member of the board of managers of Avidity NanoMedicines LLC, a private biopharmaceutical company, since November 2012 and the President and Chief Executive Officer and a member of the board of managers of Wellspring Biosciences LLC, a private biopharmaceutical company, since July 2012 and May 2012, respectively.

Dr. Wilson served as the President and Chief Executive Officer and a member of the board of directors of Intellikine, a private biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively. He has also been a member of the board of managers of Araxes Pharma LLC, a private biopharmaceutical company, since May 2012.

Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley. Dr. Wilson was selected as a director because of his background in finance and accounting and his experience in the life sciences industry.

What is Troy Edward Wilson's net worth?: The estimated net worth of Troy Edward Wilson is at least $1.85 million as of September 29th, 2025. Dr. Wilson owns 246,853 shares of Puma Biotechnology stock worth more than $1,853,866 as of April 30th. This net worth evaluation does not reflect any other investments that Dr. Wilson may own. Learn More about Troy Edward Wilson's net worth.
How do I contact Troy Edward Wilson?: The corporate mailing address for Dr. Wilson and other Puma Biotechnology executives is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. Puma Biotechnology can also be reached via phone at (424) 248-6500 and via email at [email protected]. Learn More on Troy Edward Wilson's contact information.
Has Troy Edward Wilson been buying or selling shares of Puma Biotechnology?: Troy Edward Wilson has not been actively trading shares of Puma Biotechnology during the last quarter. Most recently, Troy Edward Wilson sold 10,800 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a transaction totalling $36,720.00. Following the completion of the sale, the director now directly owns 43,550 shares of the company's stock, valued at $148,070. Learn More on Troy Edward Wilson's trading history.
Who are Puma Biotechnology's active insiders?: Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Alessandra Cesano (Director), Allison Dorval (Director), Douglas Hunt (Insider), Jeffrey Ludwig (Insider), Ann Miller (Director), Michael Miller (Director), Jay Moyes (Director), Maximo Nougues (CFO), Adrian Senderowicz (Director), Brian Stuglik (Director), Troy Wilson (Director), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?: During the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 237,586 shares worth more than $951,627.52. The most recent insider tranaction occured on January, 7th when CEO Alan H Auerbach sold 18,012 shares worth more than $105,910.56. Insiders at Puma Biotechnology own 23.3% of the company. Learn More about insider trades at Puma Biotechnology.
Information on this page was last updated on 1/7/2026.

Troy Edward Wilson Insider Trading History at Puma Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/13/2025	Sell	10,800	$3.40	$36,720.00	43,550
6/13/2024	Sell	27,000	$3.33	$89,910.00	350
6/13/2023	Sell	27,000	$3.45	$93,150.00	350
6/16/2022	Sell	27,858	$2.58	$71,873.64	27,350
6/11/2020	Sell	25,245	$9.97	$251,692.65	26,098

Troy Edward Wilson Buying and Selling Activity at Puma Biotechnology

Puma Biotechnology Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Today's Range

Now: $7.51

$7.45

$7.66

50 Day Range

MA: $6.78

$5.70

$7.80

2 Week Range

Now: $7.51

$2.85

$7.90

Volume

194,304 shs

Average Volume

375,204 shs

Market Capitalization

$382.20 million

P/E Ratio

12.31

Dividend Yield

N/A

Beta

1.19